Please assess the completion status of the following clinical trial:

Trial Title: A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old (inclusive)~* Diagnosed with PNH (white blood cell (WBC) clone \>10%)~* Lactose dehydrogenase (LD) ≥2 times the upper limit of normal~* Screening Ferritin ≥ normal and Total Iron Binding Capacity (TIBC) \< LLN based on central lab reference ranges. If a subject is receiving iron supplements at screening, the investigator must ensure that his/her dose has been stable for 8 weeks prior to enrolment and must be maintained throughout the study~* Last transfusion within 12 months prior to screening~* Platelet count of \>30,000/mm3 at the screening visit~* Absolute neutrophil count \>500/ mm3 at the screening visit~* Women of child-bearing potential (WOCBP) must have a negative pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study~* Males must agree to use protocol defined methods of contraception and agree to refrain from donating sperm for the duration of the study~* Vaccination against Neisseria meningitides types A, C, W, Y and B, Streptococcus pneumoniae and Haemophilus influenzae Type B (Hib) either within 2 years prior to Day 1 dosing, or within 14 days after starting treatment with pegcetacoplan. Unless documented evidence exists that subjects are non-responders to vaccination as evidenced by titers or display titer levels within acceptable local limits~* Willing and able to give informed consent~Exclusion Criteria:~* Prior eculizumab (Soliris®) treatment~* Active bacterial infection~* Hereditary complement deficiency~* History of bone marrow transplantation~* Concurrent severe aplastic anemia (SAA), defined as currently receiving immunosuppressive therapy for SAA including but not limited to cyclosporin A, tacrolimus, mycophenolate mofetil or anti-thymocyte globulin~* Participation in any other investigational drug trial or exposure to another investigational agent, device or procedure within 30 days~* Evidence of QTcF prolongation defined as \>450 ms for males and \>470 ms for females at screening~* Breast-feeding women~* History of meningococcal disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental: Cohort 1 (Type: EXPERIMENTAL): 270 mg/day (up to 360 mg/day from Day 29) from Day 1 to Day 364\*

Based on this trial design, predict the completion outcome and termination type (if applicable).